These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

239 related items for PubMed ID: 10695700

  • 1. A symposium: lipid management summit on improving practice outcome. Introduction.
    Ballantyne CM.
    Am J Cardiol; 2000 Feb 10; 85(3A):1A-2A. PubMed ID: 10695700
    [No Abstract] [Full Text] [Related]

  • 2. Implications of 4S evidence on baseline lipid levels.
    Durrington PN.
    Lancet; 1995 Jul 15; 346(8968):181. PubMed ID: 7661979
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Secondary prevention in a cardiology group practice and hospital setting after a heart-care initiative.
    LaBresh KA, Owen P, Alteri C, Reilly S, Albright PS, Hordes AR, Shaftel PA, Noonan TE, Stoukides CA, Kaul AF.
    Am J Cardiol; 2000 Feb 10; 85(3A):23A-29A. PubMed ID: 10695704
    [Abstract] [Full Text] [Related]

  • 5. [Helsinki Heart Study].
    Sekiya M, Ishibashi S.
    Nihon Rinsho; 2001 Mar 10; 59 Suppl 3():404-9. PubMed ID: 11347103
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Primary prevention of coronary heart disease: where do we go from here?
    Gotto AM.
    Arch Intern Med; 2001 Apr 09; 161(7):922-4. PubMed ID: 11295953
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Updating a 12-year experience with arrest and reversal therapy for coronary heart disease (an overdue requiem for palliative cardiology).
    Esselstyn CB.
    Am J Cardiol; 1999 Aug 01; 84(3):339-41, A8. PubMed ID: 10496449
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Implications of 4S evidence on baseline lipid levels.
    Jacobson TA.
    Lancet; 1995 Jul 15; 346(8968):181-2. PubMed ID: 7603245
    [No Abstract] [Full Text] [Related]

  • 12. Clinical inquiries. What is the best strategy for monitoring the lipid-lowering effects of medical therapy used for the primary prevention of coronary artery disease (CAD)?
    Sherrod JP, Krist A.
    J Fam Pract; 2001 Nov 15; 50(11):928. PubMed ID: 11711006
    [No Abstract] [Full Text] [Related]

  • 13. Ciprofibrate and lipid profile.
    Chandler HA, Batchelor AJ.
    Lancet; 1994 Jul 09; 344(8915):128-9. PubMed ID: 7912363
    [No Abstract] [Full Text] [Related]

  • 14. [Gemfibrozil: new aspects in clinical use].
    Tada N.
    Nihon Rinsho; 2001 Mar 09; 59 Suppl 3():625-30. PubMed ID: 11347143
    [No Abstract] [Full Text] [Related]

  • 15. [How to manage lipid profiles and their interpretation in patients with coronary heart disease?].
    Farnier M.
    Presse Med; 2009 Jun 09; 38(6):958-63. PubMed ID: 19376680
    [Abstract] [Full Text] [Related]

  • 16. [KLAS [Kanazawa Lipid Assessment Survey]].
    Mabuchi H, Inazu A, Higashikata T, Nohara A, Koizumi J.
    Nihon Rinsho; 2001 Mar 09; 59 Suppl 3():469-76. PubMed ID: 11347115
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Effects of lipid lowering on coronary plaques and coronary events.
    Roberts WC.
    Am J Cardiol; 1997 Oct 30; 80(8B):8H-9H. PubMed ID: 9372992
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.